Liver X receptors agonists impede hepatitis C virus infection in an Idol-dependent manner

Antiviral Research

Volumn 95, Issue 3, 2012, Pages 245-256

  Zeng, Jing ^a   Wu, Yang ^a   Liao, Qingjiao ^a   Li, Lixia ^a,b   Chen, Xinwen ^a   Chen, Xulin ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Hepatitis C virus; Idol; Liver X receptors; Low density lipoprotein receptor

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; INDUCIBLE DEGRADER OF THE LOW DENSITY LIPOPROTEIN RECEPTOR; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PROTEIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HEPATITIS C; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS INHIBITION;

ANTIVIRAL AGENTS; BENZOATES; BENZYLAMINES; CELL LINE; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPACIVIRUS; HEPATOCYTES; HUMANS; HYDROCARBONS, FLUORINATED; ORPHAN NUCLEAR RECEPTORS; SULFONAMIDES; UBIQUITIN-PROTEIN LIGASES; VIRUS INTERNALIZATION;

HEPATITIS C VIRUS;

EID: 84865302624     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.06.004     Document Type: Article

References (48)

1. Agnello V., ábel G., Elfahal M., Knight G.B., Zhang Q.-X. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 1999, 96:12766-12771.
2. André P., Komurian-Pradel F., Deforges S., Perret M., Berland J.L., Sodoyer M., Pol S., Bréchot C., Paranhos-Baccalà G., Lotteau V. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J. Virol. 2002, 76:6919-6928.
3. Andréo U., Maillard P., Kalinina O., Walic M., Meurs E., Martinot M., Marcellin P., Budkowska A. Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection. Cell. Microbiol. 2007, 9:2445-2456.
4. Barth H., Schäfer C., Adah M.I., Zhang F., Linhardt R.J., Toyoda H., Kinoshita-Toyoda A., Toida T., van Kuppevelt T.H., Depla E., von Weizsäcker F., Blum H.E., Baumert T.F. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 2003, 278:41003-41012.
5. Bełtowski J. Liver X receptors (LXR) as therapeutic targets in dyslipidemia. Cardiovasc. Ther. 2008, 26:297-316.
6. Berenbaum M.C. What is synergy?. Pharmacol. Rev. 1989, 41:93-141.
7. Bretscher A., Edwards K., Fehon R.G. ERM proteins and merlin: integrators at the cell cortex. Nat. Rev. Mol. Cell. Biol. 2002, 3:586-599.
8. Chappell D.A., Medh J.D. Receptor-mediated mechanisms of lipoprotein remnant catabolism. Prog. Lipid Res. 1998, 37:393-422.
9. Chisholm J.W., Hong J., Mills S.A., Lawn R.M. The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J. Lipid Res. 2003, 44:2039-2048.
10. Costet P., Luo Y., Wang N., Tall A.R. Sterol-dependent transactivation of theABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 2000, 275:28240-28245.
11. Dorner M., Horwitz J.A., Robbins J.B., Barry W.T., Feng Q., Mu K., Jones C.T., Schoggins J.W., Catanese M.T., Burton D.R., Law M., Rice C.M., Ploss A. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011, 474:208-211.
12. Evans M.J., von Hahn T., Tscherne D.M., Syder A.J., Panis M., Wolk B., Hatziioannou T., McKeating J.A., Bieniasz P.D., Rice C.M. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446:801-805.
13. Germi R., Crance J.-M., Garin D., Guimet J., Lortat-Jacob H., Ruigrok R.W.H., Zarski J.-P., Drouet E. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J. Med. Virol. 2002, 68:206-215.
14. Gong Q., Cheng M., Chen H., Liu X., Si Y., Yang Y., Yuan Y., Jin C., Yang W., He F., Wang J. Phospholipid scramblase 1 mediates hepatitis C virus entry into host cells. FEBS Lett. 2011, 585:2647-2652.
15. Hong C., Duit S., Jalonen P., Out R., Scheer L., Sorrentino V., Boyadjian R., Rodenburg K.W., Foley E., Korhonen L., Lindholm D., Nimpf J., van Berkel T.J.C., Tontonoz P., Zelcer N. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. J. Biol. Chem. 2010, 285:19720-19726.
16. Jamroz-Wisniewska A., Wojcicka G., Horoszewicz K., Beltowski J. Liver X receptors (LXRs). Part II: non-lipid effects, role in pathology, and therapeutic implications. Postepy Hig. Med. Dosw. (Online) 2007, 61:760-785.
17. Janowski B.A., Willy P.J., Devi T.R., Falck J.R., Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996, 383:728-731.
18. Kapadia S.B., Chisari F.V. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc. Natl. Acad. Sci. USA 2005, 102:2561-2566.
19. Kratzer A., Buchebner M., Pfeifer T., Becker T.M., Uray G., Miyazaki M., Miyazaki-Anzai S., Ebner B., Chandak P.G., Kadam R.S., Calayir E., Rathke N., Ahammer H., Radovic B., Trauner M., Hoefler G., Kompella U.B., Fauler G., Levi M., Levak-Frank S., Kostner G.M., Kratky D. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. J. Lipid Res. 2009, 50:312-326.
20. Lauer G.M., Walker B.D. Hepatitis C virus infection. New Engl. J. Med. 2001, 345:41-52.
21. Lewis G.F., Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 2005, 96:1221-1232.
22. Liu S., Yang W., Shen L., Turner J.R., Coyne C.B., Wang T. Tight junction proteins claudin-1 and Occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J. Virol. 2009, 83:2011-2014.
23. Lozach P.-Y., Amara A., Bartosch B., Virelizier J.-L., Arenzana-Seisdedos F., Cosset F.-L., Altmeyer R. C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J. Biol. Chem. 2004, 279:32035-32045.
24. Lupberger J., Zeisel M.B., Xiao F., Thumann C., Fofana I., Zona L., Davis C., Mee C.J., Turek M., Gorke S., Royer C., Fischer B., Zahid M.N., Lavillette D., Fresquet J., Cosset F.-L., Rothenberg S.M., Pietschmann T., Patel A.H., Pessaux P., Doffoel M., Raffelsberger W., Poch O., McKeating J.A., Brino L., Baumert T.F. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 2011, 17:589-595.
25. Manns M.P., Foster G.R., Rockstroh J.K., Zeuzem S., Zoulim F., Houghton M. The way forward in HCV treatment [mdash] finding the right path. Nat. Rev. Drug Discov. 2007, 6:991-1000.
26. Miao B., Zondlo S., Gibbs S., Cromley D., Hosagrahara V.P., Kirchgessner T.G., Billheimer J., Mukherjee R. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J. Lipid Res. 2004, 45:1410-1417.
27. Molina S., Castet V., Fournier-Wirth C., Pichard-Garcia L., Avner R., Harats D., Roitelman J., Barbaras R., Graber P., Ghersa P., Smolarsky M., Funaro A., Malavasi F., Larrey D., Coste J., Fabre J.-M., Sa-Cunha A., Maurel P. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J. Hepatol. 2007, 46:411-419.
28. Monazahian M., Böhme I., Bonk S., Koch A., Scholz C., Grethe S., Thomssen R. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol. 1999, 57:223-229.
29. Morrow M.P., Grant A., Mujawar Z., Dubrovsky L., Pushkarsky T., Kiselyeva Y., Jennelle L., Mukhamedova N., Remaley A.T., Kashanchi F., Sviridov D., Bukrinsky M. Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP binding cassette transporter A1. Mol. Pharmacol. 2010, 78:215-225.
30. Naik S.U., Wang X., Da Silva J.S., Jaye M., Macphee C.H., Reilly M.P., Billheimer J.T., Rothblat G.H., Rader D.J. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 2006, 113:90-97.
31. Nelson D.R. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients. Liver Int. 2011, 31:53-57.
32. Nielsen S.U., Bassendine M.F., Burt A.D., Martin C., Pumeechockchai W., Toms G.L. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J. Virol. 2006, 80:2418-2428.
33. Odds F.C. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 2003, 52:1.
34. Pöhlmann S., Zhang J., Baribaud F., Chen Z., Leslie G.J., Lin G., Granelli-Piperno A., Doms R.W., Rice C.M., McKeating J.A. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J. Virol. 2003, 77:4070-4080.
35. Petit M.-A., Lièvre M., Peyrol S., De Sequeira S., Berthillon P., Ruigrok R.W.H., Trépo C. Enveloped particles in the serum of chronic hepatitis C patients. Virology 2005, 336:144-153.
36. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A.J., Houghton M., Rosa D., Grandi G., Abrignani S. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
37. Ray K. Hepatitis: NPC1L1 identified as a novel HCV entry factor. Nat. Rev. Gastroenterol. Hepatol. 2012, 9:124.
38. Repa J.J., Turley S.D., Lobaccaro J.-M.A., Medina J., Li L., Lustig K., Shan B., Heyman R.A., Dietschy J.M., Mangelsdorf D.J. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000, 289:1524-1529.
39. Rowe A.H., Argmann C.A., Edwards J.Y., Sawyez C.G., Morand O.H., Hegele R.A., Huff M.W. Enhanced synthesis of the oxysterol 24(S), 25-epoxycholesterol in macrophages by inhibitors of 2, 3-oxidosqualene: lanosterol cyclase. Circ. Res. 2003, 93:717-725.
40. Sabol S.L., Brewer H.B., Santamarina-Fojo S. The human ABCG1 gene: identification of LXR response elements that modulate expression in macrophages and liver. J. Lipid Res. 2005, 46:2151-2167.
41. Saunier B., Triyatni M., Ulianich L., Maruvada P., Yen P., Kohn L.D. Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J. Virol. 2003, 77:546-559.
42. Scarselli E., Ansuini H., Cerino R., Roccasecca R.M., Acali S., Filocamo G., Traboni C., Nicosia A., Cortese R., Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 2002, 21:5017-5025.
43. Shimakami T., Lanford R.E., Lemon S.M. Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities. Curr. Opin. Pharm. 2009, 9:537-544.
44. Susser S., Vermehren J., Forestier N., Welker M.W., Grigorian N., Füller C., Perner D., Zeuzem S., Sarrazin C. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J. Clin. Virol. 2011, 52:321-327.
45. Wojcicka G., Jamroz-Wisniewska A., Horoszewicz K., Beltowski J. Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy Hig. Med. Dosw. (Online) 2007, 61:736-759.
46. Wong J., Quinn C.M., Gelissen I.C., Brown A.J. Endogenous 24(S), 25-epoxycholesterol fine-tunes acute control of cellular cholesterol homeostasis. J. Biol. Chem. 2008, 283:700-707.
47. Wu Y., Liao Q., Yang R., Chen X., Chen X. A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication. Virus Res. 2011, 155:406-414.
48. Zelcer N., Hong C., Boyadjian R., Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009, 325:100-104.